Ferric Carboxymaltose is a next-generation intravenous iron complex used for the treatment of iron deficiency and iron deficiency anemia, particularly in patients who cannot tolerate or do not respond adequately to oral iron supplements. It offers the advantage of high-dose iron delivery in a single administration, enabling rapid replenishment of iron stores with fewer infusions.
This water-soluble iron-carbohydrate complex consists of a ferric hydroxide core stabilized by a carboxymaltose shell, which controls the release of bioavailable iron to reduce the risk of free iron toxicity. Ferric Carboxymaltose is widely used in therapeutic areas including nephrology, gastroenterology, obstetrics and gynecology, oncology, and cardiology, especially in cases related to chronic kidney disease, inflammatory bowel disease, or postpartum anemia.
Product Highlights:
- CAS Number: 9007-72-1
- Molecular Structure: Iron(III)-hydroxide complex with carboxymaltose
- Form: Sterile injectable solution or raw API
- Color: Brown to dark brown liquid or powder (API grade)
- Iron Content: Typically, 50 mg/mL (for IV formulation)
- Usage: Parenteral iron replacement therapy
- Key Benefits: High bioavailability, reduced GI side effects, allows high-dose administration in a single sitting
Compliance & Quality:
Manufactured under stringent GMP standards, Ferric Carboxymaltose is tested for heavy metals, endotoxins, microbial limits, and iron release profile to ensure compliance with pharmacopeial and international quality requirements. Suitable for formulation into finished dosage forms or bulk supply to pharmaceutical manufacturers.
Applications:
- Treatment of iron deficiency anemia in adults and children
- Management of anemia in CKD patients
- Iron supplementation in pre/postnatal care
- Oncology-related anemia management
- Use in patients with malabsorption syndromes
